CytoSorbents is a critical care-focused therapeutic device company using blood purification to modulate the immune system, with the goal of preventing or treating multiple organ failures in life-threatening illnesses. The company’s flagship product, CytoSorb, is approved in Europe as a safe and effective extracorporeal cytokine filter. It is designed to reduce the “cytokine storm” that can cause organ failure or death.
The company reported today that it successfully completed negotiations and commenced work on the previously announced $1 million Phase II SBIR (Small Business Innovation Research) contract in trauma and burn injury from the U.S. Army. The work, supported by the U.S. Army Medical Research and Material Command, has received committed funding of $1.15 million to date.
Cytosorbents, over the next year, will continue its collaboration with some of the leading medical researchers in the U.S. military to explore the use of its CytoSorb cytokine filter and newly developed technologies to treat both trauma along with burn and smoke inhalation injuries in large animal models. After the successful completion of Phase II work, the company will be eligible to apply for a Phase III SBIR award that would then be used to fund an acceleration of human clinical testing in the areas of burn injury and/or trauma.
The company is already engaged in a separate, recently announced Air Force-funded and FDA-approved 30 patient human pilot study using CytoSorb to treat rhabdomyolysis in trauma patients. This trial will begin in the U.S. later this year.
For additional information about CytoSorbents Corporation and its flagship CytoSorb cytokine filter, please visit www.cytosorbents.com
Let us hear your thoughts below: